RFNC-VNIIEF (an enterprise of the Rosatom State Corporation) has begun working out medical methods for using the Tianox nitric oxide therapy device, the company's press service reports.
Recall that Sarov scientists have developed a device for inhalation of nitric oxide. The development called "Tianox" generates therapeutic nitrogen monoxide directly at the patient's bedside. The generator produces the gas mixture necessary for therapy at room temperature, using the air of the room where it is installed.
Currently, nitric oxide for inhalation is obtained chemically at stationary stations and delivered to medical institutions in high-pressure cylinders. This approach has a number of significant drawbacks: the need for periodic purchase of cylinders with nitrogen oxide, complex logistics and a limited shelf life of nitrogen oxide in cylinders.
The Tianox device synthesizes nitric oxide in a gas discharge from the surrounding air directly during therapy, which allows you to completely abandon the use of cylinders and significantly increase the availability of this treatment in practical medicine.Currently, the development of medical methods of using the device is carried out at the Almazov National Medical Research Center (St. Petersburg) in two clinical groups: adult patients and children. The developers of "Tianox" train doctors to work with the device, attend operations, monitor the methods of using the device in real conditions.
The device is designed for the production of inhaled nitric oxide in the treatment of a wide range of diseases. According to Academician of the Russian Academy of Sciences Alexander Chuchalin, the widespread introduction of the Tianox nitric oxide therapy device into medical practice will increase the average life expectancy in Russia by 2.5 years.
"The device has already passed technical tests in the laboratories of Roszdravnadzor and Rostest, sanitary-chemical and toxicological tests in accredited centers, as well as primary clinical testing in the leading cardiac surgery clinics of the country. In total, the device was tested for compliance with more than 230 parameters. The results confirmed that the device meets the requirements for safe use," said Alexander Shirshin, one of the developers, a leading researcher at the RFNC-VNIIEF.
The device is in demand in intensive care units and departments of anesthesiology-intensive care, cardiology, neonatology departments and perinatal centers.
The launch of the Tianox device is scheduled for the end of 2019.
Source: "Time N"